MedTrace Logo

SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)

NCT05133661 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 17602

Last updated 2025-09-17

No results posted yet for this study

Summary

The goal is to assess the feasibility and acceptability of integrating into existing health systems, provision of HPV screening and treatment of pre-cancerous cervical cancer lesions with ablative treatments in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. Study findings will inform implementation of cervical cancer prevention and treatment services as part of a global effort to eliminate cervical cancer, with particular relevance for low-and-middle income countries. This will inform country strategy and guidelines on offering integrated cervical cancer prevention and treatment services in a manner that is culturally sensitive, client oriented, and system appropriate.

Conditions

Interventions

DIAGNOSTIC_TEST

HPV testing

Interviews will be conducted among women from the general population and HIV+ women after screening for HPV. A small subset of participants will be interviewed after receiving treatment for precancer. HPV test results and outcome of the precancer treatment if indicated will be documented.

Sponsors & Collaborators

  • UNITAID

    collaborator OTHER

  • Expertise France

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • Jhpiego

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-19
Primary Completion
2025-09-05
Completion
2025-12-31

Countries

  • Burkina Faso
  • Côte d’Ivoire
  • Guatemala
  • Philippines

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05133661 on ClinicalTrials.gov